Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Vaccine pharmaceutical composition for suppressing apoptosis of ctl or inhibiting suppression of induction of ctl

A composition and drug technology, applied in the field of vaccine pharmaceutical compositions for inhibiting CTL apoptosis or blocking CTL induction inhibition, can solve problems such as inability to effectively induce antigen-specific CD8-positive T cells and the like

Inactive Publication Date: 2017-04-19
NITTO DENKO CORP
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, antigen-specific CD8-positive T cells cannot be effectively induced by administering only antigen and adjuvant

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccine pharmaceutical composition for suppressing apoptosis of ctl or inhibiting suppression of induction of ctl
  • Vaccine pharmaceutical composition for suppressing apoptosis of ctl or inhibiting suppression of induction of ctl
  • Vaccine pharmaceutical composition for suppressing apoptosis of ctl or inhibiting suppression of induction of ctl

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1、2

[0460] (Preparation of cream for transdermal administration)

[0461] A cream for transdermal administration having the composition of Table 2 below was prepared. Specifically, the following antigen peptides, the first cellular immunity induction promoter, the second cellular immunity induction promoter as a helper peptide, and dimethylmethylene were mixed with the compounding amounts shown in Table 2. 15% by weight of sulfone (DMSO) was added to the base material (primer) to make the total 100% by weight and mixed to obtain a cream for transdermal administration. The primer used was prepared by mixing according to the composition compounding materials described in Table 1.

[0462] Prepare to laminate PET film / PET non-woven fabric (with area 0.7cm 2 ) A composite substrate obtained by bonding the PET film side as the tape side to the center of the fixing adhesive tape. 4 mg of a cream for transdermal administration was applied to the non-woven fabric portion of the composite sub...

Embodiment 3～5、 comparative example 1～6

[0474] (Preparation of injection liquid preparation for subcutaneous administration)

[0475] A liquid injection preparation for subcutaneous administration having the composition shown in Table 2 below was prepared as a sample for immunization experiment. Specifically, the antigens shown above, the first cellular immunity induction promoter, and the second cellular immunity induction promoter as a helper peptide were weighed and mixed in the compounding amounts shown in Table 2, and physiological saline was added. Make 1000 μL and mix with a homogenizer to prepare an injection liquid preparation for subcutaneous administration.

[0476]

[0477] For the injection liquid preparations for subcutaneous administration obtained in the examples, the following evaluations were performed.

[0478] Mouse immunity test 2 (injection)

[0479] In accordance with the following procedure, a mouse immunization test was performed using the above-mentioned injection liquid preparation for subcutaneo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
thicknessaaaaaaaaaa
thicknessaaaaaaaaaa
Login to View More

Abstract

The purpose of the present invention is to provide a vaccine pharmaceutical composition that can be used ubiquitously to induce cellular immunity to various antigens and exhibits a high induction effect. The present invention is a vaccine pharmaceutical composition characterized by suppressing apoptosis of CTL or inhibiting suppression of the induction of CTL.

Description

Technical field [0001] The present invention relates to the inhibition of apoptosis induction of antigen-specific CD8-positive T cells. Background technique [0002] Generally, vaccines that are widely used are pathogens such as microorganisms or viruses, or substances whose toxicity is reduced or neutralized, and are administered to organisms to induce immunity for the prevention of infection. In addition, there are cancer vaccines that allow cellular immune institutions to recognize cancer cell-specific antigens and induce specific attacks on cancer cells by the cellular immune system, which are used as one of cancer treatment methods. [0003] In cancer treatment, it is also known that adjuvants are used in order to enhance the effect of cancer vaccines that induce cellular immunity. As adjuvants, for example, 1H-imidazo[4,5-C]quinolin-4-amine, imiquimod (for example, refer to [Patent Document 1]), cyclic diGMP (c-di- GMP) and other cyclic dinucleotide analogs (for example, re...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00A61K39/39A61K45/00A61P31/00A61P31/12A61P35/00A61P43/00
CPCA61K39/00A61K45/00A61K39/39A61K39/0011A61K39/0005A61K2039/54A61K2039/55511A61K2039/55516
Inventor 前田佳己冈崎有道浅利大介堀光彦
Owner NITTO DENKO CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com